148
Participants
Start Date
December 10, 2020
Primary Completion Date
September 19, 2025
Study Completion Date
March 20, 2026
Ravulizumab
Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Placebo
Matching placebo
Best supportive care
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Research Site, Brussels
Research Site, Parkville
Research Site, Chênée
Research Site, Yvoir
Research Site, Bruges
Research Site, Goyang-si
Research Site, Athens
Research Site, Pittsburgh
Research Site, Granada
Research Site, Hamburg
Research Site, Pátrai
Research Site, Durham
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Málaga
Research Site, Pamplona
Research Site, Halfa
Research Site, Udine
Research Site, Tampa
Research Site, Salamanca
Research Site, La Tronche
Research Site, Seville
Research Site, Grosse Pointe Farms
Research Site, Angers
Research Site, Ramat Gan
Research Site, Thessaloniki
Research Site, Ulm
Research Site, Seattle
Research Site, Shanghai
Research Site, Suzhou
Research Site, Tianjin
Research Site, Cerqueira César
Research Site, Florianópolis
Research Site, Jaú
Research Site, Porto Alegre
Research Site, Porto Alegre
Research Site, Rio de Janeiro
Research Site, São José do Rio Preto
Research Site, São Paulo
Research Site, Calgary
Research Site, Nice
Research Site, Roma
Research Site, Akita
Research Site, Anjo
Research Site, Chiba
Research Site, Fukushima
Research Site, Isehara-shi
Research Site, Kurashiki-shi
Research Site, Minatoku
Research Site, Okayama
Research Site, Osaka
Research Site, Osakasayama-shi
Research Site, Sapporo
Research Site, Suita-shi
Research Site, Tsukuba
Research Site, Wakayama
Research Site, Groningen
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Huddinge
Research Site, London
Research Site, Nottingham
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY